AKT1 and acute lymphoblastic leukemia: Next, we investigated to what extent either AKT inhibition or ERK inhibition, and a combination thereof, could increase the ex vivo sensitivity for prednisolone in BCP-ALL PDXs harboring an endogenous IKZF1 gene deletion (Figure 4A).